Robust Group Amplifies Wide Scale Expertise with Three Strategic Hires
Syneos Health Communications – the portfolio of Syneos Health® agencies designed to deliver insights-driven integrated communications spanning advertising & branding, public relations and medical communications – has made three strategic senior hires in Europe to enhance its client services, creative and scientific editorial offerings.
Justine Pruvot joins as client services director and will lead key accounts from the Paris office. She is charged with managing teams to develop and deliver a diverse range of global, European and French communications programs, including omnichannel campaigns, medical communications, corporate communications and public relations. For more than two decades Justine has worked with leading pharmaceutical companies including Sanofi, Amgen, Novo Nordisk, Gilead, Shire and BMS.
Gabriel Lippis will lead the creative department of Syneos Health Communications France as creative director, spearheading the teams and empowering them to expand upon their creative capabilities and offerings to deliver solutions that are rooted in integrated ideas, digital experiences and omnichannel campaigns for the European market. He is an award-winning creative director with 20 years of experience who has worked with global brands, including Samsung, Nissan, Lancôme, YSL and Martell.
Rob Pilbrow, MPhil, MSc, ISMPP CMPPTM will serve as the EU director for integrated scientific and editorial services, working with both the teams in Europe and India. With more than 15 years of global medical communications experience, he has a proven track record in creating, growing and managing high-performing scientific services and publications teams. His expertise in working effectively with a diverse range of biopharmaceutical and healthcare stakeholders in multinational environments, and managing complex projects to successful outcomes, complements the intricate work Syneos Health Communications executes on behalf of clients.
“We’re excited to welcome Justine, Gabriel and Rob to the Syneos Health Communications team. Their expertise will be invaluable as we continue to push creative boundaries and drive better results for our clients,” said Ian Dorrian, President of Syneos Health Communications Europe. “As a group that has access to a robust portfolio of 26,000 experts across Syneos Health, we operate at the intersection of humanity, technology, and creativity, executing campaigns that are formulated by those who know the industry and the work best. The addition of these three key hires speaks to the high-impact talent joining our organization. I know with their leadership and insights we will continue to build upon our unique positon in Europe.”
Notably, Justine and Gabriel will report to Dominique Marchais, who is a 2021 Healthcare Businesswoman’s Association Luminary recipient.
Syneos Health Communications: At the Heart of Health
Syneos Health Communications is a purpose-built portfolio of innovative health-first, health-only advertising, branding, medical communications, market access and public relations agencies. Fiercely focused on creating platforms that allow customers to bring life-changing healthcare solutions to the world, Syneos Health Communications is an unrivaled community — powered by 26,000 clinical and commercial minds across Syneos Health® — that operates at the intersection of health, technology, and creativity. Visit www.syneoshealthcommunications.com to learn more.
About Syneos Health
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 26,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.